15 March 2016 - The IQWiG found more positive and negative patient-relevant outcomes, which tend to cancel each other. There remains an indication of a low additional value of the use of cobimetinib in combination with vemurafenib when compared with vemurafenib monotherapy.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/cobimetinib-bei-fortgeschrittenem-melanom-mit-braf-v600-mutation-hinweis-auf-geringen-zusatznutzen.7209.html [German]